Pharmacological treatment for uterine leiomyosarcomas

Bibliography

• Toro JR, Travis LB, Wu HJ, et al. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: an analysis of 26,758 cases. Int J Cancer 2006;119:2922-30
   PubMed Web of Science ®Google Scholar
• Gadducci A, Cosio S, Romanini A, Genazzani AR. The management of patients with uterine sarcoma: a debated clinical challenge. Crit Rev Oncol Hematol 2008;65:129-42
   PubMed Web of Science ®Google Scholar
• Amant F, Coosemans A, Debiec-Rychter M, et al. Clinical management of uterine sarcomas. Lancet Oncol 2009;10:1188-98
   PubMed Web of Science ®Google Scholar
• World Health Organization. Classification of tumours. In: Tavassoli FA, Devilee P, editors. Pathology and genetics of tumours of the breast and female genital organs. IARC Press, Lyon; 2003
   Google Scholar
• Prat J. FIGO staging for uterine sarcomas. Int J Gynaecol Obstet 2009;104:177-8
   PubMed Web of Science ®Google Scholar
• Major FJ, Blessing JA, Silverberg SG, et al. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer 1993;71(4 Suppl):1702-9
   PubMed Web of Science ®Google Scholar
• Gadducci A, Landoni F, Sartori E, et al. Uterine leiomyosarcoma: analysis of treatment failures and survival. Gynecol Oncol 1996;62:25-32
   PubMed Web of Science ®Google Scholar
• Gadducci A. Prognostic factors in uterine sarcoma. Best Pract Res Clin Obstet Gynaecol 2011;25:783-95
   PubMed Web of Science ®Google Scholar
• El-Khalfaoui K, du Bois A, Heitz F, et al. Current and future options in the management and treatment of uterine sarcoma. Ther Adv Med Oncol 2014;6:21-8
   PubMed Web of Science ®Google Scholar
• Yamada S, Yamada SM, Nakaguchi H, et al. A case of multiple brain metastases of uterine leiomyosarcoma with a literature review. Surg Oncol 2011;20:e127-31
   PubMed Web of Science ®Google Scholar
• Tan LA, Kasliwal MK, Nag S, O’Toole JE. A rare intramedullary spinal cord metastasis from uterine leiomyosarcoma. J Clin Neurosci 2013;20:1309-12
   PubMed Web of Science ®Google Scholar
• Tunio MA, Al-Asiri M, Fareed MM. Uterine leiomyosarcoma metastasizing to the heart. J Coll Physicians Surg Pak 2014;24(Suppl 1):S20-1
   PubMedGoogle Scholar
• Tunio MA, Alasiri M, Saleh RM, et al. Obstructive small bowel metastasis from uterine leiomyosarcoma: a case report. Case Rep Obstet Gynecol 2014;2014:603097
   PubMedGoogle Scholar
• Gurram MK, Pulivarthi S, McGary CT, Defillo A. Brain and multiorgan metastases from uterine leiomyosarcoma. Tumori 2014;100:e8-13
   PubMedGoogle Scholar
• Ozturk S, Unver M, Ozturk BK, et al. Isolated metastasis of uterine leiomyosarcoma to the pancreas: report of a case and review of the literature. Int J Surg Case Rep 2014;5:350-3
   PubMedGoogle Scholar
• Giuntoli RLII, Metzinger DS, DiMarco CS, et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol 2003;89:460-9
   PubMed Web of Science ®Google Scholar
• Kapp DS, Shin JY, Chan JK. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer 2008;112:820-30
   PubMed Web of Science ®Google Scholar
• Seidman MA, Oduyebo T, Muto MG, et al. Peritoneal dissemination complicating morcellation of uterine mesenchymal neoplasms. PLoS One 2012;7(11):e50058
   PubMed Web of Science ®Google Scholar
• Stine JE, Clarke-Pearson DL, Gehrig PA. Uterine morcellation at the time of hysterectomy: techniques, risks, and recommendations. Obstet Gynecol Surv 2014;69:415-25
   PubMed Web of Science ®Google Scholar
• George S, Barysauskas C, Serrano C, et al. Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma. Cancer 2014;120(20):3154-8
   PubMed Web of Science ®Google Scholar
• Leibsohn S, d’Ablaing G, Mishell DRJr, Schlaerth JB. Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas. Am J Obstet Gynecol 1990;162:968-74
   PubMed Web of Science ®Google Scholar
• Takamizawa S, Minakami H, Usui R, et al. Risk of complications and uterine malignancies in women undergoing hysterectomy for presumed benign leiomyomas. Gynecol Obstet Invest 1999;48:193-6
   PubMed Web of Science ®Google Scholar
• Oduyebo T, Rauh-Hain AJ, Meserve EE, et al. The value of re-exploration in patients with inadvertently morcellated uterine sarcoma. Gynecol Oncol. 2014;132:360-5
   PubMed Web of Science ®Google Scholar
• Kho KA, Nezhat CH. Evaluating the risks of electric uterine morcellation. JAMA 2014;311:905-6
   PubMed Web of Science ®Google Scholar
• ESMO/ European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25(Suppl 3):iii102-12
   PubMedGoogle Scholar
• Reed NS, Mangioni C, Malmström H, et al. European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer 2008;44:808-18
   PubMed Web of Science ®Google Scholar
• Hensley ML, Ishill N, Soslow R, et al. Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: results of a prospective study. Gynecol Oncol 2009;112:563-7
   PubMed Web of Science ®Google Scholar
• Ricci S, Giuntoli RLII, Eisenhauer E, et al. Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma? Gynecol Oncol 2013;131:629-33
   PubMed Web of Science ®Google Scholar
• Hensley ML, Wathen JK, Maki RG, et al. Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005). Cancer 2013;119:1555-61
   PubMed Web of Science ®Google Scholar
• Mancari R, Signorelli M, Gadducci A, et al. Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients. Gynecol Oncol 2014;133:531-6
   PubMed Web of Science ®Google Scholar
• Leitao MM, Brennan MF, Hensley M, et al. Surgical resection of pulmonary and extrapulmonary recurrences of uterine leiomyosarcoma. Gynecol Oncol 2002;87:287-94
   PubMed Web of Science ®Google Scholar
• Giuntoli RLII, Garrett-Mayer E, Bristow RE, Gostout BS. Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma. Gynecol Oncol 2007;106:82-8
   PubMed Web of Science ®Google Scholar
• Burt BM, Ocejo S, Mery CM, et al. Repeated and aggressive pulmonary resections for leiomyosarcoma metastases extends survival. Ann Thorac Surg 2011;92:1202-7
   PubMed Web of Science ®Google Scholar
• Leitao MMJr, Zivanovic O, Chi DS, et al. Surgical cytoreduction in patients with metastatic uterine leiomyosarcoma at the time of initial diagnosis. Gynecol Oncol 2012;125:409-13
   PubMed Web of Science ®Google Scholar
• Patel SR, Vadhan-Raj S, Papadopolous N, et al. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies- dose-response and schedule dependence. J Clin Oncol 1997;15:2378-84
   PubMed Web of Science ®Google Scholar
• Benjamin RS, Legha SS, Patel SR, Nicaise C. Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience. Cancer Chemother Pharmacol 1993;31(Suppl 2):S174-9
   PubMed Web of Science ®Google Scholar
• Farid M, Ong WS, Tan MH, et al. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease. Am J Clin Oncol 2013;36:368-74
   PubMed Web of Science ®Google Scholar
• Martin-Liberal J, Benson C. Systemic chemotherapy for inoperable, locally advanced, recurrent or metastatic uterine leiomyosarcoma. Clin Oncol (R Coll Radiol) 2013;25:343-5
   PubMed Web of Science ®Google Scholar
• Italiano A, Toulmonde M, Stoeckle E, et al. Clinical outcome of leiomyosarcomas of vascular origin: comparison with leiomyosarcomas of other origin. Ann Oncol 2010;21:1915-21
   PubMed Web of Science ®Google Scholar
• Omura GA, Major FJ, Blessing JA, et al. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 1983;52:626-32
   PubMed Web of Science ®Google Scholar
• Sutton GP, Blessing JA, Rosenshein N, et al. Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncologic Group study). Am J Obstet Gynecol 1989;161:309-12
   PubMed Web of Science ®Google Scholar
• Sutton G, Blessing JA, Park R, et al. Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: a study of the Gynecologic Oncology Group. Obstet Gynecol 1996;87:747-50
   PubMed Web of Science ®Google Scholar
• Sutton GP, Blessing JA, Barrett RJ, McGehee R. Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Am J Obstet Gynecol 1992;166:556-9
   PubMed Web of Science ®Google Scholar
• Sutton G, Blessing JA, Malfetano JH. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 1996;62:226-9
   PubMed Web of Science ®Google Scholar
• Look KY, Sandler A, Blessing JA, Gynecologic Oncology Group (GOG) Study. Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study. Gynecol Oncol 2004;92:644-7
   PubMed Web of Science ®Google Scholar
• Hensley ML, Blessing JA, Mannel R, Rose PG. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol 2008;109:329-34
   PubMed Web of Science ®Google Scholar
• Hensley ML, Blessing JA, Degeest K, et al. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol 2008;109:323-8
   PubMed Web of Science ®Google Scholar
• Grunewald R, Kantarjian H, Keating MJ, et al. Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (Gemcitabine) administration in leukemia. Cancer Res 1990;50:6823-6
   PubMed Web of Science ®Google Scholar
• Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991;9:491-8
   PubMed Web of Science ®Google Scholar
• García-Del-Muro X, López-Pousa A, Maurel J, et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol 2011;29:2528-33
   PubMed Web of Science ®Google Scholar
• Anderson S, Aghajanian C. Temozolomide in uterine leiomyosarcomas. Gynecol Oncol 2005;98:99-103
   PubMed Web of Science ®Google Scholar
• Ferriss JS, Atkins KA, Lachance JA, et al. Temozolomide in advanced and recurrent uterine leiomyosarcoma and correlation with o6-methylguanine DNA methyltransferase expression: a case series. Int J Gynecol Cancer 2010;20:120-5
   PubMed Web of Science ®Google Scholar
• Ridolfi C, Pasini G, Drudi F, et al. Long lasting clinical response to chemotherapy for advanced uterine leiomyosarcoma: a case report. J Med Case Rep 2013;7:29
   PubMedGoogle Scholar
• Jiang G, Jiang AJ, Xin Y, et al. Progression of O6-methylguanine-DNA methyltransferase and temozolomide resistance in cancer research. Mol Biol Rep 2014. [ Epub ahead of print]
   Web of Science ®Google Scholar
• Fayette J, Coquard IR, Alberti L, et al. ET-743: a novel agent with activity in soft-tissue sarcomas. Curr Opin Oncol 2006;18:347-53
   PubMed Web of Science ®Google Scholar
• D’Incalci M, Galmarini CM. A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther 2010;9:2157-63
   PubMed Web of Science ®Google Scholar
• Allavena P, Signorelli M, Chieppa M, et al. Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res 2005;65:2964-71
   PubMed Web of Science ®Google Scholar
• Germano G, Frapolli R, Belgiovine C, et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 2013;23:249-62
   PubMed Web of Science ®Google Scholar
• D’Incalci M, Badri N, Galmarini CM, Allavena P. Trabectedin, a drug acting on both cancer cells and the tumour microenvironment. Br J Cancer 2014;111:646-50
   PubMed Web of Science ®Google Scholar
• D’Angelo D, Borbone E, Palmieri D, et al. The impairment of the High Mobility Group A (HMGA) protein function contributes to the anticancer activity of trabectedin. Eur J Cancer 2013;49:1142-51
   PubMed Web of Science ®Google Scholar
• Grosso F, Dileo P, Sanfilippo R, et al. Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. Eur J Cancer 2006;42:1484-90
   PubMed Web of Science ®Google Scholar
• Skorupa A, Beldner M, Kraft A, Montero AJ. Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma. Cancer Biol Ther 2007;6:1015-17
   PubMed Web of Science ®Google Scholar
• Stoyianni A, Kapodistrias N, Kampletsas E, et al. Trabectedin-related rhabdomyolysis: an uncommon but fatal toxicity. Tumori 2011;97:252-5
   PubMed Web of Science ®Google Scholar
• Takebayashi Y, Pourquier P, Zimonjic DB, et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 2001;7:961-6
   PubMed Web of Science ®Google Scholar
• Casado JA, Río P, Marco E, et al. Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin. Mol Cancer Ther 2008;7:1309-18
   PubMed Web of Science ®Google Scholar
• Schöffski P, Taron M, Jimeno J, et al. Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study. Eur J Cancer 2011;47:1006-12
   PubMed Web of Science ®Google Scholar
• Tewari D, Saffari B, Cowan C, et al. Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcoma. Gynecol Oncol 2006;102:421-4
   PubMed Web of Science ®Google Scholar
• Amant F, Coosemans A, Renard V, et al. Clinical outcome of ET-743 (Trabectedin; Yondelis) in high-grade uterine sarcomas: report on five patients and a review of the literature. Int J Gynecol Cancer 2009;19:245-8
   PubMed Web of Science ®Google Scholar
• Judson I, Blay J, Chawla S, et al. Trabectedin in the treatment of advanced uterine leiomyosarcomas: results of a pooled analysis of five single-agent phase II studies using the recommended dose. J Clin Oncol 2010;28(15s Suppl):abstract 10028
   Google Scholar
• Sanfilippo R, Grosso F, Jones RL, et al. Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers. Gynecol Oncol 2011;123:553-6
   PubMed Web of Science ®Google Scholar
• Monk BJ, Blessing JA, Street DG, et al. A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study. Gynecol Oncol 2012;124:48-52
   PubMed Web of Science ®Google Scholar
• Hollebecque A, Adenis A, Taieb S, et al. Inadequacy of size-based response criteria to assess the efficacy of trabectedin among metastatic sarcoma patients. Invest New Drugs 2010;28:529-30
   PubMed Web of Science ®Google Scholar
• Sanfilippo R, Casali PG. The intriguing patterns of tumor response to trabectedin. Expert Rev Anticancer Ther 2013;13(6 Suppl 1):21-4
   PubMed Web of Science ®Google Scholar
• Kasper B, Schmitt T, Wuchter P, et al. The use of positron emission tomography in soft tissue sarcoma patients under therapy with trabectedin. Mar Drugs 2009;7:331-40
   PubMed Web of Science ®Google Scholar
• Payne MJ, Macpherson RE, Bradley KM, Hassan AB. Trabectedin in advanced high-grade uterine leiomyosarcoma: a case report illustrating the value of (18)FDG-PET-CT in assessing treatment response. Case Rep Oncol 2014;7:132-8
   PubMedGoogle Scholar
• Schutz FA, Choueiri TK, Sternberg CN. Pazopanib: clinical development of a potent anti-angiogenic drug. Crit Rev Oncol Hematol 2011;77:163-7
   PubMed Web of Science ®Google Scholar
• Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 2009;27:3126-32
   PubMed Web of Science ®Google Scholar
• van der Graaf WT, Blay JY, Chawla SP, et al. EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379:1879-86
   PubMed Web of Science ®Google Scholar
• Hardman MP, Roman JJ, Burnett AF, Santin AD. Metastatic uterine leiomyosarcoma regression using an aromatase inhibitor. Obstet Gynecol 2007;110:518-20
   PubMed Web of Science ®Google Scholar
• O’Cearbhaill R, Zhou Q, Iasonos A, et al. Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors. Gynecol Oncol 2010;116:424-9
   PubMed Web of Science ®Google Scholar
• Altman AD, Nelson GS, Chu P, et al. Uterine sarcoma and aromatase inhibitors: tom Baker Cancer Centre experience and review of the literature. Int J Gynecol Cancer 2012;22:1006-12
   PubMed Web of Science ®Google Scholar
• Leitao MMJr, Hensley ML, Barakat RR, et al. Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcoma. Gynecol Oncol 2012;124:558-62
   PubMed Web of Science ®Google Scholar
• George S, Feng Y, Manola J, et al. Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors. Cancer 2014;120:738-43
   PubMed Web of Science ®Google Scholar
• Uchida T, Nakakawaji K, Sakamoto J, et al. The effectiveness of medroxyprogesterone in the treatment of multiple metastasizing leiomyosarcomas: report of a case. Surg Today 1996;26:138-41
   PubMed Web of Science ®Google Scholar
• Koivisto-Korander R, Leminen A, Heikinheimo O. Mifepristone as treatment of recurrent progesterone receptor-positive uterine leiomyosarcoma. Obstet Gynecol 2007;109:512-14
   PubMed Web of Science ®Google Scholar
• Li L, Schuster IP, Jacob R, et al. Potential benefit of hormonal therapy for non-uterine soft tissue sarcoma (STS) - a case report and literature review. Springerplus 2013;2:536
   PubMedGoogle Scholar
• Thigpen JT, Blessing JA, Beecham J, et al. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol 1991;9:1962-6
   PubMed Web of Science ®Google Scholar
• Muss HB, Bundy BN, Adcock L, Beecham J. Mitoxantrone in the treatment of advanced uterine sarcoma. A phase II trial of the Gynecologic Oncology Group. Am J Clin Oncol 1990;13:32-4
   PubMed Web of Science ®Google Scholar
• Asbury R, Blessing JA, Buller R, et al. Amonafide in patients with leiomyosarcoma of the uterus: a phase II Gynecologic Oncology Group study. Am J Clin Oncol 1998;21:145-6
   PubMed Web of Science ®Google Scholar
• Rose PG, Blessing JA, Soper JT, Barter JF. Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol 1998;70:267-71
   PubMed Web of Science ®Google Scholar
• Miller DS, Blessing JA, Kilgore LC, et al. Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study. Am J Clin Oncol 2000;23:355-7
   PubMed Web of Science ®Google Scholar
• Sutton G, Blessing JA, Ball H. Phase II trial of paclitaxel in leiomyosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol 1999;74:346-9
   PubMed Web of Science ®Google Scholar
• Smith HO, Blessing JA, Vaccarello L. Trimetrexate in the treatment of recurrent or advanced leiomyosarcoma of the uterus: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2002;84:140-4
   PubMed Web of Science ®Google Scholar
• McMeekin DS, Sill MW, Darcy KM, et al. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study. Gynecol Oncol 2007;106:596-603
   PubMed Web of Science ®Google Scholar
• Hensley ML, Sill MW, Scribner DRJr, et al. Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol 2009;115:460-5
   PubMed Web of Science ®Google Scholar
• Okouneva T, Azarenko O, Wilson L, et al. Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther 2008;7:2003-11
   PubMed Web of Science ®Google Scholar
• Schöffski P, Ray-Coquard IL, Cioffi A, et al. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol 2011;12:1045-52
   PubMed Web of Science ®Google Scholar
• D’Adamo DR, Anderson SE, Albritton K, et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 2005;23:7135-42
   PubMed Web of Science ®Google Scholar
• Verschraegen CF, Arias-Pulido H, Lee SJ, et al. Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen. Ann Oncol 2012;23:785-90
   PubMed Web of Science ®Google Scholar
• Hensley ML, Miller A, O’Malley DM, et al. A randomized phase III trial of gemcitabine + docetaxel + bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol 2014;32:519-26. In press
   PubMed Web of Science ®Google Scholar
• Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002;99:11393-8
   PubMed Web of Science ®Google Scholar
• Mackay HJ, Buckanovich RJ, Hirte H, et al. A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia. Gynecol Oncol 2012;125:136-40
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005;307:1098-101
   PubMed Web of Science ®Google Scholar
• Setsu N, Yamamoto H, Kohashi K, et al. The Akt/mammalian target of rapamycin pathway is activated and associated with adverse prognosis in soft tissue leiomyosarcomas. Cancer 2012;118:1637-48
   PubMed Web of Science ®Google Scholar
• Wong TF, Takeda T, Li B, et al. Curcumin disrupts uterine leiomyosarcoma cells through AKT-mTOR pathway inhibition. Gynecol Oncol 2011;122:141-8
   PubMed Web of Science ®Google Scholar
• Wong TF, Takeda T, Li B, et al. Curcumin targets the AKT-mTOR pathway for uterine leiomyosarcoma tumor growth suppression. Int J Clin Oncol 2014;19:354-63
   PubMed Web of Science ®Google Scholar
• Hernando E, Charytonowicz E, Dudas ME, et al. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med 2007;13:748-53
   PubMed Web of Science ®Google Scholar
• Italiano A, Kind M, Stoeckle E, et al. Temsirolimus in advanced leiomyosarcomas: patterns of response and correlation with the activation of the mammalian target of rapamycin pathway. Anticancer Drugs 2011;22:463-7
   PubMed Web of Science ®Google Scholar
• Mach CM, Urh A, Anderson ML. Bowel perforation associated with temsirolimus use in a recently irradiated patient. Am J Health Syst Pharm 2014;71:919-23
   PubMed Web of Science ®Google Scholar
• Vader G, Lens SM. The Aurora kinase family in cell division and cancer. Biochim Biophys Acta 2008;1786:60-72
   PubMed Web of Science ®Google Scholar
• Karthigeyan D, Prasad SB, Shandilya J, et al. Biology of Aurora A kinase: implications in cancer manifestation and therapy. Med Res Rev 2011;1:757-93
   Google Scholar
• Katayama H, Brinkly WR, Sen S. The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev 2003;22:451-64
   PubMedGoogle Scholar
• Arkenau HT, Plummer R, Molife LR, et al. A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies. Ann Oncol 2012;23:1307-13
   PubMed Web of Science ®Google Scholar
• Umene K, Banno K, Kisu I, et al. Aurora kinase inhibitors: potential molecular-targeted drugs for gynecologic malignant tumors. Biomed Rep 2013;1:335-40
   PubMedGoogle Scholar
• Shan W, Akinfenwe P, Brewer Savannah K, et al. A small-molecular inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma. Clin Cancer Res 2012;18:3352-65
   PubMed Web of Science ®Google Scholar
• Brewer Savannah KJ, Demicco EG, Lusby K, et al. Dual targeting of mTOR and aurora-A kinase for the treatment of uterine Leiomyosarcoma. Clin Cancer Res 2012;18:4633-45
   PubMed Web of Science ®Google Scholar
• Gupta AA, Yao X, Verma S, et al. Chemotherapy (gemcitabine, docetaxel plus gemcitabine, doxorubicin, or trabectedin) in inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma: a clinical practice guideline. Curr Oncol 2013;20:e448-54
   PubMed Web of Science ®Google Scholar
• Pautier P, Floquet A, Penel N, et al. Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study). Oncologist 2012;17:1213-20
   PubMed Web of Science ®Google Scholar
• Van Glabbeke M, Verweij J, Judson I, Nielsen OS; EORTC Soft Tissue and Bone Sarcoma Group. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002;38:543-9
   PubMed Web of Science ®Google Scholar
• Dizon DS, Birrer MJ. Advances in the diagnosis and treatment of uterine sarcomas. Discov Med 2014;17:339-45
   PubMed Web of Science ®Google Scholar